Healthcare / Drug Manufacturers - Specialty & GenericNSE
$108.12
-4.21 (-3.84%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 20%
FCF escenarios
weak_data · normalized FCF $36.8M · quality 46.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
49/100
C
Piotroski
6/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$10.0B
P/E
901.0x
↑EV/EBITDA
18.5x
↑ROE
7.4%
↑Gross Margin
66.5%
↑Debt/Equity
0.21
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+0.7%
FCF CAGR
+11.9%
FCF margin
4.8%
FCF / Net income
0.65x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $4.00B · net income $298.3M · FCF $192.8M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $4.00B | $4.00B | $3.77B | $3.44B | $3.91B |
| Net Income | $298.3M | $298.3M | $435.2M | $569.0M | $728.8M |
| EBITDA | $581.0M | $581.0M | $733.2M | $910.0M | $1.11B |
| EPS | 3.24 | 3.24 | 4.72 | 6.17 | 7.91 |
| Gross Margin | 66.5% | 66.5% | 62.9% | 64.9% | 61.2% |
| Operating Margin | 9.8% | 9.8% | 10.4% | 16.5% | 22.0% |
| Net Margin | 7.5% | 7.5% | 11.6% | 16.5% | 18.6% |
| Balance Sheet | |||||
| Debt/Equity | 0.21 | 0.21 | 0.25 | 0.27 | 0.28 |
| Cash Flow | |||||
| Free Cash Flow | $192.8M | $192.8M | $36.8M | $-126.6M | $137.7M |
| Returns | |||||
| ROE | 7.4% | 7.4% | 11.5% | 16.8% | 25.4% |
| Valuation | |||||
| P/E | 901.00 | 901.00 | 48.92 | 20.74 | 11.91 |
| EV/EBITDA | 18.48 | 18.48 | 30.21 | 13.84 | 8.34 |
| P/B | 2.48 | 2.48 | 5.64 | 3.47 | 3.02 |
| Growth & Yield | |||||
| Revenue Growth | 6.2% | 6.2% | 9.3% | -12.0% | — |
| EPS Growth | -31.4% | -31.4% | -23.5% | -22.0% | — |
| Dividend Yield | 0.4% | 0.4% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
43.6%
EPS terminal req.
$9.59
Spread vs growth
-75.0%
5Y implied EPS CAGR
29.1%
EPS terminal req.
$11.61
Spread vs growth
-60.4%
10Y implied EPS CAGR
19.2%
EPS terminal req.
$18.70
Spread vs growth
-50.5%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-26.0%
Start / end P/E
30.4x → 32.5x
EPS bridge
4.72 → 3.24
Residual
-2.2%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.